Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (30)
NITAG documentation (1591)
Reports (55)
SAGE documentation (218)
Scientific publications (112)
Systematic reviews (SYSVAC) (2750)
Regions
Africa (267)
Americas (762)
Eastern Mediterranean (48)
Europe (704)
South-East Asia (78)
Western Pacific (196)
Diseases
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4756 results found
2016
∙
Ismael Ortega-Sanchez
Cost-Effectiveness of Meningococcal Vaccination in HIV Infected People in the US
2016
∙
Tom Shimabukuro
End-of-Season Update: 2015-2016 Influenza Vaccine Safety Monitoring
2016
∙
J Mansi
FLUCELVAX QUADRIVALENT® (Influenza Vaccine) – ccIIV4
2016
∙
WHO
Global Advisory Committee on Vaccine Safety, 15–16 June 2016
2016
∙
Elissa Meites
GRADE process for 2-dose schedules
2016
∙
Karen Wong
GRADE Review and Work Group Plans
2016
∙
Monica Patton
GRADE: MenACWY Vaccines for HIV-Infected Persons
2016
∙
AL Reingold
Hepatitis Vaccines Introduction
2016
∙
Elissa Meites
HPV Vaccines Work Group Plans
2016
∙
Bruce L Innis
Immunogenicity and Safety of GSK’s FluLaval™ Quadrivalent Inactivated Influenza Vaccine in Children 6-35 Months of Age
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register